Oct. 25 at 2:49 PM
$NRXP http://Investing.com - H.C. Wainwright has reiterated its Buy rating and
$40.00 price target on NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), citing positive implications from a recent FDA approval for a competitor’s drug. According to InvestingPro data, NRXP has shown remarkable momentum with a 158% return over the past year, despite recent volatility. Analyst consensus remains strongly bullish, with price targets ranging from
$25 to
$46.
